BALANCE: Understanding Quality of Life for Black and Mixed Men with Prostate Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

BALANCE is a prospective, patient-reported outcomes study that collects surveys from men diagnosed with prostate cancer to explore quality of life and mental health across different treatments. It focuses on communities underrepresented in research, especially Black and mixed-ethnicity men, using electronic or hardcopy questionnaires. The study aims to identify disparities in post-treatment experiences to inform supportive care and improve equity in outcomes. Participation involves consenting adults 18 and older who have access to the survey platform and can complete the PROMs questionnaire, with results accessible across sessions if needed.

Why it matters

Who can join: the full rules

Inclusion Criteria:

In order to be eligible to participate in this study, a subject must meet all of the following criteria:

* Age ≥ 18 years;
* Be of either:

  * Black African ancestry; OR
  * Black African-Caribbean ancestry; OR
  * Mixed Black ancestry.
* Diagnosed with PCa;
* Assigned male at birth;
* Participants with access to digital devices (smartphones, tablets, computers) or able to complete hardcopy versions of the survey;
* Participants willing to participate and provide informed consent.

Exclusion Criteria:

A potential subject who meets any of the following criteria will be excluded from participation in this study:

* Participants having no diagnosis of PCa;
* Participants unable to provide consent;
* Participants assigned female at birth.

Where it's running

• The Erasmus MC
  Rotterdam, Arnhem, Netherlands Recruiting

Study contacts

• Study coordinator: Esther Robijn
• Email: e.robijn@uroweb.org
• Phone: +31 (0)26 389 0680

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

• Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer

  This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.

  Recruiting at 8 sites Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Benidorm, Alicante and 9 other locations · NCT07860528

• Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence

  This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.

  Recruiting Phase 2 University Hospital Tuebingen · Heidelberg, Baden-Wurttemberg and 3 other locations · NCT07860047

• Lutetium-177 Ludotadipep for advanced prostate cancer

  This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.

  Recruiting at 7 sites Phase 3 FutureChem · Gyeonggi-do and 7 other locations · NCT07853209

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.